Miraculins

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Miraculins today said that it has successfully completed a two-part ISO certification audit conducted by the BSI Group.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Miraculins yesterday said that it has received a C$1 million (US$986,000) non-convertible secured loan from Gretchen Ross.

The company said that if all warrants are exercised on or before expiration of the early exercise period, Miraculins expects to receive gross proceeds of around C$780,000.

Bloom Burton will provide financial modeling, an assessment of financing options, an evaluation of partnership opportunities, and other services.

The biomarker-based diagnostics firm sold 10.2 million units at C$.05 each.

The biomarker-based diagnostics firm will use the placement funding for R&D and corporate purposes.

Inverness, through its Biosite division, will develop and evaluate tests using Miraculins' panel of 35 biomarkers for placenta development and preeclampsia.

Miraculins will work with the Israel-based firm on a program to develop biomarker-based diagnostics for determining preeclampsia risk.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.